IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Purchased by Avestar Capital LLC

Avestar Capital LLC increased its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 759 shares of the company’s stock after buying an additional 60 shares during the quarter. Avestar Capital LLC’s holdings in IDEXX Laboratories were worth $383,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Chicago Partners Investment Group LLC raised its holdings in shares of IDEXX Laboratories by 16.7% during the third quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company’s stock worth $340,000 after purchasing an additional 96 shares during the last quarter. Manning & Napier Advisors LLC purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $20,418,000. Oppenheimer Asset Management Inc. lifted its holdings in shares of IDEXX Laboratories by 13.8% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company’s stock valued at $5,825,000 after buying an additional 1,453 shares during the period. National Pension Service boosted its stake in shares of IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company’s stock worth $93,957,000 after buying an additional 12,647 shares during the last quarter. Finally, EFG Asset Management Americas Corp. grew its holdings in IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company’s stock worth $6,201,000 after acquiring an additional 3,966 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Up 1.1 %

IDXX stock opened at $421.76 on Thursday. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $583.39. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The firm has a 50-day simple moving average of $455.52 and a 200-day simple moving average of $479.07. The stock has a market capitalization of $34.54 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.74 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, topping the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to analyst estimates of $980.32 million. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. IDEXX Laboratories’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the previous year, the business earned $2.53 EPS. Equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of analyst reports. Barclays decreased their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Piper Sandler reiterated a “neutral” rating and issued a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Stifel Nicolaus dropped their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.